Acid-secretory response and parietal cell sensitivity in patients with duodenal ulcer before and after treatment with sucralfate or ranitidine
- PMID: 2735330
- DOI: 10.1016/0002-9343(89)90177-0
Acid-secretory response and parietal cell sensitivity in patients with duodenal ulcer before and after treatment with sucralfate or ranitidine
Abstract
Patients with endoscopically proved duodenal ulcer were randomly assigned to treatment with either ranitidine 300 mg at bedtime or sucralfate 2 g twice daily for six weeks. Acid-secretory studies were performed before commencement and 60 to 84 hours after cessation of treatment and endoscopic healing was confirmed. Patients were randomly assigned to receive a constant infusion of secretory stimulant: either pentagastrin 0.1 and 6.0 micrograms/kg/hour or histamine acid phosphate 4.0 and 40 micrograms/kg/hour. Acid output in mmol/hour was measured for basal, low dose, and high dose output. Parietal cell sensitivity (PCS) was calculated as the ratio of low-dose acid output: high-dose acid output and expressed as a percentage. Values before and after treatment were compared and significance of differences was determined using the Student paired t test. There was an apparent decrease in basal acid output, low-dose acid output, high-dose acid output, and PCS with ulcer healing, regardless of treatment or stimulant used. Basal acid output, low-dose acid output, high-dose acid output, and PCS were significantly lower in the sucralfate-treated group, but only high-dose acid output decreased significantly in the ranitidine-treated group. These differences may be relevant to early duodenal ulcer relapse in ranitidine-treated patients.
Similar articles
-
Changes in nocturnal and peak acid outputs after duodenal ulcer healing with sucralfate or ranitidine.Gut. 1992 Feb;33(2):175-8. doi: 10.1136/gut.33.2.175. Gut. 1992. PMID: 1541412 Free PMC article.
-
Gastric acid secretory response in Helicobacter pylori-positive patients with duodenal ulcer disease.Can J Gastroenterol. 2001 Jan;15(1):29-39. doi: 10.1155/2001/764615. Can J Gastroenterol. 2001. PMID: 11173324 Clinical Trial.
-
Acid secretory responses and parietal cell sensitivity following duodenal ulcer healing with omeprazole, sucralfate, and Maalox.Am J Med. 1991 Aug 8;91(2A):91S-94S. doi: 10.1016/0002-9343(91)90457-9. Am J Med. 1991. PMID: 1882910 Clinical Trial.
-
Acid secretory changes and early relapse following duodenal ulcer healing with ranitidine or sucralfate.Am J Med. 1991 Aug 8;91(2A):95S-101S. doi: 10.1016/0002-9343(91)90458-a. Am J Med. 1991. PMID: 1882911 Review.
-
Treatment of duodenal ulcer with sucralfate.Scand J Gastroenterol Suppl. 1991;185:22-8. doi: 10.3109/00365529109093216. Scand J Gastroenterol Suppl. 1991. PMID: 1683491 Review.
Cited by
-
Optimizing acid suppression for treatment of acid-related diseases.Dig Dis Sci. 1995 Feb;40(2 Suppl):24S-49S. doi: 10.1007/BF02214870. Dig Dis Sci. 1995. PMID: 7859582 Review.
-
Changes in nocturnal and peak acid outputs after duodenal ulcer healing with sucralfate or ranitidine.Gut. 1992 Feb;33(2):175-8. doi: 10.1136/gut.33.2.175. Gut. 1992. PMID: 1541412 Free PMC article.
-
Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.Drugs. 1989 Jun;37(6):801-70. doi: 10.2165/00003495-198937060-00003. Drugs. 1989. PMID: 2667937 Review.
-
The H2-receptor antagonist era in duodenal ulcer disease.Yale J Biol Med. 1992 Nov-Dec;65(6):639-48;discussion 689-92. Yale J Biol Med. 1992. PMID: 1364125 Free PMC article. Review.
-
Helicobacter pylori eradication, duodenal ulcer healing, and gastric secretory state.Gut. 1994 Apr;35(4):571. doi: 10.1136/gut.35.4.571. Gut. 1994. PMID: 8175003 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources